CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant...

V Urzì Brancati, C Scarpignato, L Minutoli, G Pallio - Biomedicines, 2022 - mdpi.com

Immunosuppressant drugs (ISDs) are routinely used in clinical practice to maintain organ
transplant survival. However, these drugs are characterized by a restricted therapeutic …

被引用次数：16 相关文章所有 9 个版本

[PDF] frontiersin.org

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

E Mendrinou, ME Mashaly, AM Al Okily… - Frontiers in …, 2020 - frontiersin.org

Background Tacrolimus is an approved first-line immunosuppressive agent for kidney
transplantations. Part of interindividual and interethnic differences in the response of …

被引用次数：17 相关文章所有 6 个版本

[PDF] researchgate.net

Influence of CYP3A422* and CYP3A53* combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients

AHIM Ebid, DA Ismail, NM Lotfy… - Journal of Clinical …, 2022 - Wiley Online Library

Background Tacrolimus is a widely prescribed immunosuppressant agent for kidney
transplantation. However, optimal dosing is challenging due to its narrow therapeutic index …

被引用次数：5 相关文章所有 5 个版本

[HTML] lww.com

[HTML][HTML] Clinical implications of tacrolimus time in therapeutic range and intrapatient variability in urban renal transplant recipients undergoing early corticosteroid …

DR Pierce, P West-Thielke, Z Hajjiri… - Transplantation …, 2021 - journals.lww.com

Background. Tacrolimus demonstrates wide intrapatient and interpatient variability requiring
therapeutic drug monitoring. The utility of tacrolimus time in therapeutic range (TTR) after …

被引用次数：7 相关文章所有 5 个版本

[PDF] umich.edu

Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients

AD Leino, JM Park, AL Pasternak - … : The Journal of Human …, 2021 - Wiley Online Library

Abstract Study Objective This study investigated the effect of CYP3A5 phenotype on time in
therapeutic range (TTR) of tacrolimus post‐transplant in pediatric patients. Design and Data …

被引用次数：6 相关文章所有 5 个版本

[PDF] whuhzzs.com

[PDF][PDF] 五酯胶囊提升他克莫司浓度与供肝CYP3A5 基因多态性的相关性

马景胜，杨文涛，朱红飞，武雅君 - 中国中西医结合消化杂志, 2022 - zxyxhen.whuhzzs.com

目的: 探讨肝移植受者术后使用五酯胶囊提升他克莫司浓度与供肝CYP3A5 基因多态性是否存在
相关性. 方法: 肝移植术后, 40 例连续服用五酯胶囊6 个月的患者为试验组, 46 …

被引用次数：1 相关文章所有 4 个版本

[HTML] nih.gov

Predictive capacity of population pharmacokinetic models for the tacrolimus dose requirements of pediatric solid organ transplant recipients

AL Pasternak, JM Park, MP Pai - Therapeutic drug monitoring, 2023 - journals.lww.com

Background: Transplant recipients require individualized tacrolimus doses to maximize graft
survival. Multiple pediatric tacrolimus population pharmacokinetic (PopPK) models …

被引用次数：2 相关文章所有 7 个版本